Posted on 13/01/2010 in Pharmaceutical Company Product News Daiichi Sankyo has pointed out the results of a new study, which show that Effient - the oral antiplatelet agent it co-developed with Eli Lilly and Ube Industries - is more cost-effective than other exisiting treatments.
The drug is currently indicated for use in patients with acute coronary syndrome (ACS) and prevents blood platelets from clumping together and blocking arteries.
According to the study, compared with existing treatment clopidogrel, Effient decreases cumulative medical costs by 136 pounds per patient over a period of 14.7 months.
The results were featured in the publication Circulation on January 5th 2010.
David Cohen, a professor of medicine who was involved in the study, commented: "These analyses are important because the results provide the healthcare community, including formulary decision makers, with new data regarding the cost-effectiveness of Effient for patients with ACS."
In other Daiichi Sankyo news, the firm revealed last week that its subsidiary Luitpold Pharmaceuticals has acquired PharmaForce.Other news stories from 13/01/2010
Read more in the Zenopa News Archive
How this news is generated
|
